Prostate cancer chemoprevention

Seminars in Oncology

Volumn 40, Issue 3, 2013, Pages 276-285

  Sandhu, Gurdarshan S ^a   Nepple, Kenneth G ^a   Tanagho, Youssef S ^a   Andriole, Gerald L ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; DUTASTERIDE; FINASTERIDE; PLACEBO; ROFECOXIB; SELENIUM; TOREMIFENE;

ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CARCINOGENESIS; CHEMOPROPHYLAXIS; GLEASON SCORE; HUMAN; MOLECULAR PATHOLOGY; MORBIDITY; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE VOLUME; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADRENERGIC ALPHA-ANTAGONISTS; ANIMALS; ANTICARCINOGENIC AGENTS; CHEMOPREVENTION; DIET; HUMANS; MALE; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SELENIUM; VITAMIN E;

EID: 84879434018     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2013.04.003     Document Type: Article

References (82)

1. M.B. Sporn, and D.L. Newton Chemoprevention of cancer with retinoids Fed Proc 38 1979 2528 2534
2. M.L. Gonzalgo, and W.B. Isaacs Molecular pathways to prostate cancer J Urol 170 2003 2444 2452
3. J.I. Epstein, and M. Herawi Prostate needle biopsies containing prostatic intraepithelial neoplasia or atypical foci suspicious for carcinoma: implications for patient care J Urol 175 2006 820 834
4. W.A. Sakr, D.J. Grignon, and G.P. Haas Age and racial distribution of prostatic intraepithelial neoplasia Eur Urol 30 1996 138 144
5. I.J. Powell, C.H. Bock, and J.J. Ruterbusch Evidence supports a faster growth rate and/or earlier transformation to clinically significant prostate cancer in black than in white American men, and influences racial progression and mortality disparity J Urol 183 2010 1792 1796
6. K. Stamatiou, A. Alevizos, and E. Agapitos Incidence of impalpable carcinoma of the prostate and of non-malignant and precarcinomatous lesions in Greek male population: an autopsy study Prostate 66 2006 1319 1328
7. I.M. Thompson, P.J. Goodman, and C.M. Tangen The influence of finasteride on the development of prostate cancer N Engl J Med 349 2003 215 224
8. G.L. Andriole, D.G. Bostwick, and O.W. Brawley Effect of dutasteride on the risk of prostate cancer N Engl J Med 362 2010 1192 1202
9. P.C. Walsh Chemoprevention of prostate cancer N Engl J Med 362 2010 1237 1238
10. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2012 CA Cancer J Clin 62 2012 10 29
11. T.A. Stamey, N. Yang, and A.R. Hay Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate N Engl J Med 317 1987 909 916
12. W.J. Catalona, D.S. Smith, and T.L. Ratliff Measurement of prostate-specific antigen in serum as a screening test for prostate cancer N Engl J Med 324 1991 1156 1161
13. H.G. Welch, and W.C. Black Overdiagnosis in cancer J Natl Cancer Inst 102 2010 605 613
14. G. Draisma, R. Etzioni, and A. Tsodikov Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context J Natl Cancer Inst 101 2009 374 383
15. R. Etzioni, D.F. Penson, and J.M. Legler Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends J Natl Cancer Inst 94 2002 981 990
16. D. Telesca, R. Etzioni, and R. Gulati Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends Biometrics 64 2008 10 19
17. M. McGregor, J.A. Hanley, and J.F. Boivin Screening for prostate cancer: estimating the magnitude of overdetection Cmaj 159 1998 1368 1372
18. G.L. Andriole, E.D. Crawford, and R.L. Grubb 3rd Mortality results from a randomized prostate-cancer screening trial N Engl J Med 360 2009 1310 1319
19. M.R. Cooperberg, J.M. Broering, and P.R. Carroll Time trends and local variation in primary treatment of localized prostate cancer J Clin Oncol 28 2010 1117 1123
20. M.G. Sanda, R.L. Dunn, and J. Michalski Quality of life and satisfaction with outcome among prostate-cancer survivors N Engl J Med 358 2008 1250 1261
21. A.B. Mariotto, K.R. Yabroff, and Y. Shao Projections of the cost of cancer care in the United States: 2010-2020 J Natl Cancer Inst 103 2011 117 128
22. L.S. Wilson, R. Tesoro, and E.P. Elkin Cumulative cost pattern comparison of prostate cancer treatments Cancer 109 2007 518 527
23. P.L. Nguyen, X. Gu, and S.R. Lipsitz Cost implications of the rapid adoption of newer technologies for treating prostate cancer J Clin Oncol 29 2011 1517 1524
24. S.M. Lippman, E.A. Klein, and P.J. Goodman Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT) JAMA 301 2009 39 51
25. W.D. Steers 5alpha-reductase activity in the prostate Urology 58 2001 17 24
26. G. Andriole, D. Bostwick, and O. Brawley Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial J Urol 172 2004 1314 1317
27. G.L. Andriole, H.A. Guess, and J.I. Epstein Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial. PLESS Study Group. Proscar Long-term Efficacy and Safety Study Urology 52 1998 195 201
28. J.D. McConnell, C.G. Roehrborn, and O.M. Bautista The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia N Engl J Med 349 2003 2387 2398
29. G.L. Andriole, C. Roehrborn, and C. Schulman Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia Urology 64 2004 537 541
30. C.G. Roehrborn, P. Siami, and J. Barkin The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study Eur Urol 57 2010 123 131
31. J.D. McConnell, R. Bruskewitz, and P. Walsh The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group N Engl J Med 338 1998 557 563
32. Wilt TJ, MacDonald R, Hagerty K, et al. Five-alpha-reductase Inhibitors for prostate cancer prevention. Cochrane Database Syst Rev. 2008:CD007091.
33. J.T. Wei Limitations of a contemporary prostate biopsy: the blind march forward Urol Oncol 28 2010 546 549
34. Y.C. Cohen, K.S. Liu, and N.L. Heyden Detection bias due to the effect of finasteride on prostate volume: a modeling approach for analysis of the Prostate Cancer Prevention Trial J Natl Cancer Inst 99 2007 1366 1374
35. M.W. Redman, C.M. Tangen, and P.J. Goodman Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach Cancer Prev Res (Phila) 1 2008 174 181
36. S.A. Kaplan, C.G. Roehrborn, and A.G. Meehan PCPT: evidence that finasteride reduces risk of most frequently detected intermediate- and high-grade (Gleason score 6 and 7) cancer Urology 73 2009 935 939
37. P. Pinsky, H. Parnes, and L. Ford Estimating rates of true high-grade disease in the prostate cancer prevention trial Cancer Prev Res (Phila) 1 2008 182 186
38. I.M. Thompson, C. Chi, and D.P. Ankerst Effect of finasteride on the sensitivity of PSA for detecting prostate cancer J Natl Cancer Inst 98 2006 1128 1133
39. I.M. Thompson, C.M. Tangen, and P.J. Goodman Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection J Urol 177 2007 1749 1752
40. C.M. Moinpour, A.K. Darke, and G.W. Donaldson Longitudinal analysis of sexual function reported by men in the Prostate Cancer Prevention Trial J Natl Cancer Inst 99 2007 1025 1035
41. US Food and Drug Administration. Accessed April 25, 2012, at http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm299754.htm.
42. R.S. Svatek, J.J. Lee, and C.G. Roehrborn Cost-effectiveness of prostate cancer chemoprevention: a quality of life-years analysis Cancer 112 2008 1058 1065
43. S.D. Reed, C.D. Scales Jr, and S.B. Stewart Effects of family history and genetic polymorphism on the cost-effectiveness of chemoprevention with finasteride for prostate cancer J Urol 185 2011 841 847
44. L.N. Thomas, C.B. Lazier, and R. Gupta Differential alterations in 5alpha-reductase type 1 and type 2 levels during development and progression of prostate cancer Prostate 63 2005 231 239
45. R. Choo, C. Danjoux, and G. Morton How much does Gleason grade of follow-up biopsy differ from that of initial biopsy in untreated, Gleason score 4-7, clinically localized prostate cancer? Prostate 67 2007 1614 1620
46. US Food and Drug Administration Drug Safety Communication. Accessed April 29, 2012, at http://www.fda.gov/Drugs/DrugSafety/ucm258314.htm.
47. M.R. Theoret, Y.M. Ning, and J.J. Zhang The risks and benefits of 5alpha-reductase inhibitors for prostate-cancer prevention N Engl J Med 365 2011 97 99
48. Supplementary appendix to REDUCE trial. Accessed April 29, 2012, at http://www.nejm.org/doi/suppl/10.1056/NEJMoa0908127/suppl-file/ nejm-andriole-1192sa1.pdf.
49. P.C. Albertsen, J.A. Hanley, and J. Fine 20-year outcomes following conservative management of clinically localized prostate cancer JAMA 293 2005 2095 2101
50. G.L. Lu-Yao, P.C. Albertsen, and D.F. Moore Outcomes of localized prostate cancer following conservative management JAMA 302 2009 1202 1209
51. P.C. Albertsen, D.F. Moore, and W. Shih Impact of comorbidity on survival among men with localized prostate cancer J Clin Oncol 29 2011 1335 1341
52. S.R. Earnshaw, C.L. McDade, and L.K. Black Cost effectiveness of 5-alpha reductase inhibitors for the prevention of prostate cancer in multiple patient populations Pharmacoeconomics 28 2010 489 505
53. M.W. Kattan, S.R. Earnshaw, and C.L. McDade Cost effectiveness of chemoprevention for prostate cancer with dutasteride in a high-risk population based on results from the REDUCE clinical trial Appl Health Econ Health Policy 9 2011 305 315
54. I. Leav, S.M. Ho, and P. Ofner Biochemical alterations in sex hormone-induced hyperplasia and dysplasia of the dorsolateral prostates of Noble rats J Natl Cancer Inst 80 1988 1045 1053
55. I. Leav, F.B. Merk, and P.W. Kwan Androgen-supported estrogen-enhanced epithelial proliferation in the prostates of intact Noble rats Prostate 15 1989 23 40
56. S. Raghow, M.Z. Hooshdaran, and S. Katiyar Toremifene prevents prostate cancer in the transgenic adenocarcinoma of mouse prostate model Cancer Res 62 2002 1370 1376
57. D. Price, B. Stein, and P. Sieber Toremifene for the prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia: results of a double-blind, placebo controlled, phase IIB clinical trial J Urol 176 2006 965 970
58. GTx shares dive after toremifene flunks PhIII cancer trial. Fierce Biotech. Accessed May 7, 2012, at http://www.fiercebiotech.com/story/gtx-shares- dive-after-toremifene-flunks-phiii-cancer-trial/2010-05-26.
59. R.O. Roberts, D.J. Jacobson, and C.J. Girman A population-based study of daily nonsteroidal anti-inflammatory drug use and prostate cancer Mayo Clinic Proc 77 2002 219 225
60. J. Irani, V. Ravery, and J.L. Pariente Effect of nonsteroidal anti-inflammatory agents and finasteride on prostate cancer risk J Urol 168 2002 1985 1988
61. M.F. Leitzmann, M.J. Stampfer, and J. Ma Aspirin use in relation to risk of prostate cancer Cancer Epidemiol Biomarkers Prev 11 2002 1108 1111
62. A.E. Norrish, R.T. Jackson, and C.U. McRae Non-steroidal anti-inflammatory drugs and prostate cancer progression Int J Cancer 77 1998 511 515
63. I.M. Thompson Chemoprevention of prostate cancer: agents and study designs J Urol 178 2007 S9 S13
64. S. Bonovas, K. Filioussi, and N.M. Sitaras Statin use and the risk of prostate cancer: a metaanalysis of 6 randomized clinical trials and 13 observational studies IInt J Cancer 123 2008 899 904
65. O.P. Heinonen, D. Albanes, and J. Virtamo Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial J Natl Cancer Inst 90 1998 440 446
66. L.C. Clark, B. Dalkin, and A. Krongrad Decreased incidence of prostate cancer with selenium supplementation: results of a double-blind cancer prevention trial Br J Urol 81 1998 730 734
67. A.J. Duffield-Lillico, B.L. Dalkin, and M.E. Reid Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial BJU Int 91 2003 608 612
68. J. Virtamo, P. Pietinen, and J.K. Huttunen Incidence of cancer and mortality following alpha-tocopherol and beta-carotene supplementation: a postintervention follow-up JAMA 290 2003 476 485
69. E. Lonn, J. Bosch, and S. Yusuf Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial JAMA 293 2005 1338 1347
70. E.A. Klein, I.M. Thompson Jr., and C.M. Tangen Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT) JAMA 306 2011 1549 1556
71. S. Bonovas, A. Tsantes, and T. Drosos Cancer chemoprevention: a summary of the current evidence Anticancer Res 28 2008 1857 1866
72. M.C. Lee, A.S. Moussa, and C. Yu Multifocal high grade prostatic intraepithelial neoplasia is a risk factor for subsequent prostate cancer J Urol 184 2010 1958 1962
73. J.R. Marshall, C.M. Tangen, and W.A. Sakr Phase III trial of selenium to prevent prostate cancer in men with high-grade prostatic intraepithelial neoplasia: SWOG S9917 Cancer Prev Res (Phila) 4 2011 1761 1769
74. A.R. Kristal, and S.M. Lippman Nutritional prevention of cancer: new directions for an increasingly complex challenge J Natl Cancer Inst 101 2009 363 365
75. B.S. Kramer, K.L. Hagerty, and S. Justman Use of 5-alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline J Clin Oncol 27 2009 1502 1516
76. R. Chou, J.M. Croswell, and T. Dana Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force Ann Intern Med 155 2011 375 385
77. Briefing information and slides presented at the December 1, 2010 meeting of the Oncologic Drugs Advisory Committee Food and Drug Administration. Accessed April 29, 2012, at http://www.fda.gov/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/ucm195226.htm.
78. N.E. Fleshner, M.S. Lucia, and B. Egerdie Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial Lancet 379 2012 1103 1111
79. R.C. van den Bergh, I.J. Korfage, and C.H. Bangma Psychological aspects of active surveillance Curr Opin Urol 22 2012 237 242
80. K.K. Carroll, and H.T. Khor Dietary fat in relation to tumorigenesis Prog Biochem Pharmacol 10 1975 308 353
81. K.Y. Wolin, K. Carson, and G.A. Colditz Obesity and cancer Oncologist 15 2010 556 565
82. M.D. Fesinmeyer, R. Gulati, and S. Zeliadt Effect of population trends in body mass index on prostate cancer incidence and mortality in the United States Cancer Epidemiol Biomarkers Prev 18 2009 808 815